guest ::
| Home > Publications database > Pathology of Combined Hepatocellular Carcinoma-Cholangiocarcinoma: An Update. |
| Home > Publications database > Pathology of Combined Hepatocellular Carcinoma-Cholangiocarcinoma: An Update. |
| Journal Article (Review Article) | DKFZ-2023-00146 |
; ;
2023
MDPI
Basel
This record in other databases: 
Please use a persistent id in citations: doi:10.3390/cancers15020494
Abstract: Combined hepatocellular carcinoma-cholangiocarcinoma (cHCC-CCA) is a rare primary liver cancer that is composed of both hepatocellular and cholangiocellular differentiated cells. It is slightly more common in men and among Asian and Pacific islanders. Overall, risk factors are similar to classic risk factors of hepatocellular carcinoma (HCC). The classification has significantly evolved over time. The last WHO classification (2019) mainly emphasized diagnosis on morphological basis with routine stainings, discarded previously recognized classifications with carcinomas with stem cell features, introduced intermediate cell carcinoma as a specific subtype and considered cholangiolocarcinoma as a subtype of cholangiocellular carcinoma. Immunohistochemical markers may be applied for further specification but have limited value for diagnosis. Recent discoveries in molecular pathway regulation may pioneer new therapeutic approaches for this poor prognostic and challenging diagnosis.
Keyword(s): cHCC-CCA ; cholangiocarcinoma ; combined hepatocellular and cholangiocellular carcinoma ; hepatocellular carcinoma ; hippo signaling ; mixed carcinoma ; progenitor cells ; stem cells ; wnt signaling
; 
; 
; Article Processing Charges ; BIOSIS Previews ; Biological Abstracts ; Clarivate Analytics Master Journal List ; DOAJ Seal ; Ebsco Academic Search ; Essential Science Indicators ; Fees ; IF >= 5 ; JCR ; PubMed Central ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection
|
The record appears in these collections: |
